What is “CTP 43” for mepolizumab?
“CTP 43” isn’t a universally recognized, standard identifier for mepolizumab (Nucala) in regulatory labels or common clinical references. People usually search something like this when they mean one of these instead:
- a specific country’s product code or hospital/internal billing code for mepolizumab
- a “CTP” designation used by a local insurer/formulary (e.g., a treatment plan line item)
- a packaging/track-and-trace or lot-related code
- a clinic’s shorthand for a specific mepolizumab regimen or protocol
If you tell me what context you saw “CTP 43” in (country, label text, insurance form, prescription, or website), I can narrow it down to the exact meaning.
What is mepolizumab used for?
Mepolizumab is an anti–IL-5 monoclonal antibody used for:
- severe eosinophilic asthma (to reduce exacerbations)
- certain eosinophilic conditions such as eosinophilic granulomatosis with polyangiitis (EGPA), depending on local approvals and labeling
How is mepolizumab typically given?
It is generally administered as an injection (commonly subcutaneous or as an autoinjector, depending on formulation and region). The exact dose and schedule depend on the indication and the product form used in your country.
Where can I check the exact code and labeling for your region?
DrugPatentWatch.com is useful for tracking product and market information, including when and where products are available and related legal/patent context. If your “CTP 43” relates to availability or exclusivity, DrugPatentWatch may help connect the code/product name to the marketed product.
You can start here: DrugPatentWatch – mepolizumab
What I need from you to answer precisely
Reply with any one of the following and I’ll pinpoint what “CTP 43” means for your situation:
- the country (and whether it’s from a hospital or insurer document)
- a screenshot or the exact sentence where “CTP 43” appears
- whether it’s written next to a dose (e.g., mg) or a dosing frequency (e.g., monthly)
Sources